Clinic
VK New England Management LLC
VK New England Management LLC was paid $3.05M by Medicaid between Jan 2018 and Dec 2024, across 32 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 33% of everything it billed.
33Billing provider infoVK NEW ENGLAND MANAGEMENT LLC
LAWRENCE, MA 01840
LAWRENCE, MA 01840
33aNPI1114263449assigned 12/13/2012
33bProvider typeAdult Mental Health Clinic/Center
28Total paid$3.05M
24GClaims72,320
24DCodes billed32
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Adult Mental Health Clinic/Center providers in Massachusetts
Rank by total paid#5 of 20
Median peer was paid$222K
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,940 | $621K | |
| 2019 | 16,005 | $588K | |
| 2020 | 8,963 | $336K | |
| 2021 | 6,626 | $305K | |
| 2022 | 8,022 | $336K | |
| 2023 | 9,378 | $438K | |
| 2024incomplete | 7,386 | $422K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 33% | 22,585 | 17,669 | $999K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 28% | 8,363 | 6,879 | $847K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 18% | 8,975 | 7,407 | $561K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 13% | 13,351 | 10,124 | $404K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 4.5% | 2,740 | 2,194 | $138K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 355 | 344 | $28K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 476 | 476 | $26K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 192 | 192 | $14K |
| 92015 | Determination of refractive state | <1% | 777 | 777 | $11K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 58 | 58 | $6K |
| T1502 | Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit | <1% | 39 | 12 | $3K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 25 | 24 | $3K |
20 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 81 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 137 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 14 | $1K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 13 | $693.23 |
| 96127 | <1% | 208 | $181.43 | |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 43 | $103.37 |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 363 | $0.00 |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | 0% | 748 | $0.00 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 1,215 | $0.00 |
| G8950 | Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented | 0% | 660 | $0.00 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 30 | $0.00 |
| 1101F | 0% | 15 | $0.00 | |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 1,756 | $0.00 |
| 4320F | 0% | 1,912 | $0.00 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 4,821 | $0.00 |
| 4004F | 0% | 1,987 | $0.00 | |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 100 | $0.00 |
| G8753 | Most recent systolic blood pressure >= 140 mmhg | 0% | 162 | $0.00 |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 54 | $0.00 |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | 0% | 65 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMOHAMED, ZOSER (CEO)